Literature DB >> 27494817

Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.

Romuald Girard1, Maged D Fam1, Hussein A Zeineddine1, Huan Tan1, Abdul Ghani Mikati1, Changbin Shi1, Michael Jesselson1, Robert Shenkar1, Meijing Wu1, Ying Cao1, Nicholas Hobson1, Henrik B W Larsson2,3, Gregory A Christoforidis4, Issam A Awad1.   

Abstract

OBJECTIVE Vascular permeability and iron leakage are central features of cerebral cavernous malformation (CCM) pathogenesis. The authors aimed to correlate prospective clinical behavior of CCM lesions with longitudinal changes in biomarkers of dynamic contrast-enhanced quantitative permeability (DCEQP) and quantitative susceptibility mapping (QSM) assessed by MRI. METHODS Forty-six patients with CCMs underwent 2 or more permeability and/or susceptibility studies in conjunction with baseline and follow-up imaging and clinical surveillance during a mean 12.05 months of follow-up (range 2.4-31.27 months). Based on clinical and imaging features, cases/lesions were classified as stable, unstable, or recovering. Associated and predictive changes in quantitative permeability and susceptibility were investigated. RESULTS Lesional mean permeability and QSM values were not significantly different in stable versus unstable lesions at baseline. Mean lesional permeability in unstable CCMs with lesional bleeding or growth increased significantly (+85.9% change; p = 0.005), while mean permeability in stable and recovering lesions did not significantly change. Mean lesional QSM values significantly increased in unstable lesions (+44.1% change; p = 0.01), decreased slightly with statistical significance in stable lesions (-3.2% change; p = 0.003), and did not significantly change in recovering lesions. Familial cases developing new lesions during the follow-up period showed a higher background brain permeability at baseline (p = 0.001), as well as higher regional permeability (p = 0.003) in the area that would later develop a new lesion as compared with the homologous contralateral brain region. CONCLUSIONS In vivo assessment of vascular permeability and iron deposition on MRI can serve as objective and quantifiable biomarkers of disease activity in CCMs. This may be applied in natural history studies and may help calibrate clinical trials. The 2 techniques are likely applicable in other disorders of vascular integrity and iron leakage such as aging, hemorrhagic microangiopathy, and traumatic brain injury.

Entities:  

Keywords:  AUC = area under the curve; CCM = cerebral cavernous malformation; DCEQP = dynamic contrast-enhanced quantitative permeability; IRB = institutional review board; QSM = quantitative susceptibility mapping; ROC = receiver operating characteristic; ROCK = RhoA kinase; ROI = region of interest; SWI = susceptibility-weighted imaging; WMF = white matter far from the lesion; WMN = white matter near the lesion; biomarker; cerebral cavernous malformation; df = degrees of freedom; dynamic contrast-enhanced quantitative permeability; iron; quantitative susceptibility mapping; vascular disorders

Mesh:

Substances:

Year:  2016        PMID: 27494817      PMCID: PMC6421857          DOI: 10.3171/2016.5.JNS16687

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  42 in total

Review 1.  Statistical methods in epidemiology. v. Towards an understanding of the kappa coefficient.

Authors:  A S Rigby
Journal:  Disabil Rehabil       Date:  2000-05-20       Impact factor: 3.033

2.  Statistical analysis of correlated data using generalized estimating equations: an orientation.

Authors:  James A Hanley; Abdissa Negassa; Michael D deB Edwardes; Janet E Forrester
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

Review 3.  The kappa statistic in reliability studies: use, interpretation, and sample size requirements.

Authors:  Julius Sim; Chris C Wright
Journal:  Phys Ther       Date:  2005-03

4.  Unfolding knowledge on cerebral cavernous malformations.

Authors:  Issam A Awad
Journal:  Surg Neurol       Date:  2005-04

5.  Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion.

Authors:  Judith Gault; Robert Shenkar; Peter Recksiek; Issam A Awad
Journal:  Stroke       Date:  2005-02-17       Impact factor: 7.914

6.  Spectrum of genotype and clinical manifestations in cerebral cavernous malformations.

Authors:  Judith Gault; Stephan Sain; Ling-Jia Hu; Issam A Awad
Journal:  Neurosurgery       Date:  2006-12       Impact factor: 4.654

7.  Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation.

Authors:  Fritz-Georg Lehnhardt; Ulrich von Smekal; Benedikt Rückriem; Werner Stenzel; Michael Neveling; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Arch Neurol       Date:  2005-04

8.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis.

Authors:  Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

9.  Susceptibility-weighted imaging for the evaluation of patients with familial cerebral cavernous malformations: a comparison with t2-weighted fast spin-echo and gradient-echo sequences.

Authors:  J M de Souza; R C Domingues; L C H Cruz; F S Domingues; T Iasbeck; E L Gasparetto
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-18       Impact factor: 3.825

Review 10.  Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board.

Authors:  Rustam Al-Shahi Salman; Michel J Berg; Leslie Morrison; Issam A Awad
Journal:  Stroke       Date:  2008-10-30       Impact factor: 7.914

View more
  27 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

2.  RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.

Authors:  Robert Shenkar; Changbin Shi; Cecilia Austin; Thomas Moore; Rhonda Lightle; Ying Cao; Lingjiao Zhang; Meijing Wu; Hussein A Zeineddine; Romuald Girard; David A McDonald; Autumn Rorrer; Carol Gallione; Peter Pytel; James K Liao; Douglas A Marchuk; Issam A Awad
Journal:  Stroke       Date:  2016-11-22       Impact factor: 7.914

3.  Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Authors:  Romuald Girard; Hussein A Zeineddine; Maged D Fam; Anoop Mayampurath; Ying Cao; Changbin Shi; Robert Shenkar; Sean P Polster; Michael Jesselson; Ryan Duggan; Abdul-Ghani Mikati; Gregory Christoforidis; Jorge Andrade; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Transl Stroke Res       Date:  2017-08-17       Impact factor: 6.829

4.  Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial.

Authors:  Marc C Mabray; Arvind Caprihan; Jeffrey Nelson; Charles E McCulloch; Atif Zafar; Helen Kim; Blaine L Hart; Leslie Morrison
Journal:  Transl Stroke Res       Date:  2019-10-23       Impact factor: 6.829

5.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

6.  Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.

Authors:  Nicholas Hobson; Sean P Polster; Ying Cao; Kelly Flemming; Yunhong Shu; John Huston; Chandra Y Gerrard; Reed Selwyn; Marc Mabray; Atif Zafar; Romuald Girard; Julián Carrión-Penagos; Yu Fen Chen; Todd Parrish; Xiaohong Joe Zhou; James I Koenig; Robert Shenkar; Agnieszka Stadnik; Janne Koskimäki; Alexey Dimov; Dallas Turley; Timothy Carroll; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2019-09-12       Impact factor: 4.813

7.  Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.

Authors:  Hussein A Zeineddine; Romuald Girard; Ying Cao; Nicholas Hobson; Maged D Fam; Agnieszka Stadnik; Huan Tan; Jingjing Shen; Kiranj Chaudagar; Robert Shenkar; Richard E Thompson; Nichol McBee; Daniel Hanley; Timothy Carroll; Gregory A Christoforidis; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2017-08-09       Impact factor: 4.813

Review 8.  Familial Cerebral Cavernous Malformations.

Authors:  Atif Zafar; Syed A Quadri; Mudassir Farooqui; Asad Ikram; Myranda Robinson; Blaine L Hart; Marc C Mabray; Catherine Vigil; Alan T Tang; Mark L Kahn; Howard Yonas; Michael T Lawton; Helen Kim; Leslie Morrison
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

9.  Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.

Authors:  Romuald Girard; Hussein A Zeineddine; Janne Koskimäki; Maged D Fam; Ying Cao; Changbin Shi; Thomas Moore; Rhonda Lightle; Agnieszka Stadnik; Kiranj Chaudagar; Sean Polster; Robert Shenkar; Ryan Duggan; David Leclerc; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Circ Res       Date:  2018-05-02       Impact factor: 17.367

10.  Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.

Authors:  Miguel Alejandro Lopez-Ramirez; Angela Pham; Romuald Girard; Tine Wyseure; Preston Hale; Atsuki Yamashita; Janne Koskimäki; Sean Polster; Laleh Saadat; Ignacio A Romero; Charles T Esmon; Frederic Lagarrigue; Issam A Awad; Laurent O Mosnier; Mark H Ginsberg
Journal:  Blood       Date:  2018-11-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.